Compare Adaptive Biotechnologies Corp (ADPT) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs JetBlue Airways Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $25.05 (market cap $4.04B), while JetBlue Airways Corporation trades at $5.82 (market cap $2.19B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, JetBlue Airways Corporation nearer its low. Which is the better fit depends on your goals.
| ADPT | JBLU | |
|---|---|---|
Market Cap | $4.04B | $2.19B |
Sector | Health | Industrials |
52-Week High | $25.45 | $6.46 |
52-Week Low | $12.30 | $4.03 |
Enterprise Value | $4.10B | $9.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
JetBlue (JBLU) trades at $5.64, down 7.08% amid a recent analyst downgrade. The stock shows a bullish technical signal with oversold RSI conditions, but fundamentals reveal persistent losses with a -9.32% net margin and negative ROE of -44.36%. Recent Q2 2026 earnings beat expectations, yet revenue trends remain volatile, and cash flow from operations turned negative in 2025. The company is implementing strategic fare changes and targeting 2028 profitability.
The outlook is cautious; while cost initiatives and premium product expansions offer long-term potential, high debt levels, fuel cost pressures, and inconsistent earnings pose significant risks. Analyst consensus is mixed with a hold-heavy rating and a $5.18 price target slightly below the current price, reflecting skepticism about near-term recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
